Randomized study of high-dose chemotherapy plus rituximab (R-HDS) vs conventional chemotherapy with rituximab (R-FC) in chronic lymphocytic leukemia at high risk.

Trial Profile

Randomized study of high-dose chemotherapy plus rituximab (R-HDS) vs conventional chemotherapy with rituximab (R-FC) in chronic lymphocytic leukemia at high risk.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2014

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top